Egg Allergy Pipeline Insight Report 2021 Featuring Aimmune Therapeutics, ASIT biotech, DBV Technologies, Alladapt Immunotherapeutics –

October 5, 2021 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Egg Allergy – Pipeline Insight, 2021” clinical trials has been added to’s offering.

This “Egg allergy – Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Egg allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Egg allergy R&D. The therapies under development are focused on novel approaches to treat/improve Egg allergy.

Egg allergy Emerging Drugs Chapters

This segment of the Egg allergy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Egg allergy Emerging Drugs

AR201: Aimmune Therapeutics

AR201 is an investigational biological drug for use in oral immunotherapy for egg allergy. AR201 is based on the company’s platform Characterised Oral Desensitization ImmunoTherapy (CODIT) platform which involves desensitizing patients with defined amounts of key allergens, thereby providing a meaningful level of protection against allergic reactions. The drug is in Phase II clinical studies for the treatment of hen-egg allergy.

ADP101: Alladapt Immunotherapeutics

ADP101 is a proprietary, standardized, oral immunotherapy drug candidate that is being studied for the treatment of food allergy. The drug is in Phase I/II clinical studies for the treatment of food allergy.

Egg allergy: Therapeutic Assessment

This segment of the report provides insights about the different Egg allergy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Egg allergy

There are approx. 4+ key companies which are developing the therapies for Egg allergy. The companies which have their Egg allergy drug candidates in the most advanced stage, i.e. Phase II include, Aimmune Therapeutics.

Egg allergy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Egg allergy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Egg allergy drugs.

Key Questions Answered

  • How many companies are developing Egg allergy drugs?
  • How many Egg allergy drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Egg allergy?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Egg allergy therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Egg allergy and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Aimmune Therapeutics
  • ASIT biotech
  • DBV Technologies
  • Alladapt Immunotherapeutics

Key Products

  • AR201
  • ASIT+TM product candidate ASIT biotech
  • Viaskin Egg
  • ADP101

For more information about this clinical trials report visit


Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900